Email updates

Keep up to date with the latest news and content from BMC Health Services Research and BioMed Central.

Open Access Research article

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

Nikos Maniadakis1, Georgia Kourlaba1*, Theodoros Mougiakos2, Ioannis Chatzimanolis3 and Linus Jonsson4

Author Affiliations

1 Department of Health Services Organization & Management, National School of Public Health, 196 Alexandras Avenue, Athens 11521, Greece

2 Psychiatric clinic, 414 Military Hospital, Athens, Greece

3 Psychiatry Department, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece

4 Optuminsight, Stockholm, Sweden

For all author emails, please log on.

BMC Health Services Research 2013, 13:173  doi:10.1186/1472-6963-13-173

Published: 10 May 2013



Major depressive disorder (MDD) constitutes an important public health problem, as it is highly prevalent in the industrialized world and it is associated with substantial economic consequences for patients, health care providers, insurance and social security organizations and employers. To conduct an economic evaluation comparing agomelatine with other commonly used alternatives for treating patients with major depressive disorder (MDD) in Greece.


An existing international Markov model designed to evaluate the cost-effectiveness of agomelatine was adapted to the Greek setting. It reflects six different health states, in which patients may move on a monthly basis. The analysis was undertaken from a societal perspective. Transition probabilities, utilities and costs assigned to each health state were extracted from the published literature, government sources and expert opinion. Data reflects the year 2012 and was discounted using a rate of 3.5%. Probabilistic analysis was undertaken to deal with uncertainty.


Base case analyses revealed that agomelatine is a dominant therapy for MDD relative to escitalopram, fluoxetine and sertraline, and it appeared to be cost-effective compared to venlafaxine (ICER: €547/QALY). Agomelatine remained a dominant treatment against generic sertraline and fluoxetine, and it appeared to be a cost-effective alternative compared to generic venlafaxine and escitalopram (ICER: €1,446/QALY and €3,303/QALY, respectively). Excluding the indirect cost from the analysis, agomelatine remained a cost-effective alternative over all comparators. In the probabilistic sensitivity analysis agomelatine was dominant in 44.5%, 89.6%, 70.6% and 84.6% of simulated samples against branded venlafaxine, escitalopram, fluoxetine and sertraline, respectively.


The present evaluation indicates that agomelatine is either a dominant or a cost-effective alternative relative to branded or generic alternatives, in Greece.

Depression; Cost-effectiveness; Cost-utility; Agomelatine; Greece